'Ozempic butt' reveals the hidden side effects of rapid weight loss

A growing number of people have reported changes in their appearance after losing weight, including a condition sometimes called 'Ozempic butt'. This term describes loose, saggy skin and reduced muscle in the buttock area. While often linked to weight loss drugs like Ozempic or Wegovy, the issue can arise from any rapid or significant weight reduction, regardless of method.

The condition occurs when fat and muscle shrink faster than the skin can adapt. Rapid weight loss—whether from medication, diet, exercise, or surgery—can leave the skin unable to bounce back quickly. Factors like age, how long someone has been obese, and the total amount of weight lost also play a role in how pronounced these changes become.

Healthcare professionals often recommend gradual weight loss—around one to two pounds per week—to reduce the risk. Staying hydrated, eating enough protein, and doing strength-training exercises can help preserve muscle and skin elasticity. If 'Ozempic butt' does develop, allowing time for the body to adjust or consulting a plastic surgeon may offer solutions.

While no official global statistics track this specific side effect, anecdotal reports on social media and in medical discussions suggest it is a recognised concern. However, major medical journals have not yet published widespread formal data on the issue as of early 2026. Researchers have called for further studies to better understand how newer, highly effective obesity medications affect muscle during weight loss.

The problem is not unique to drugs like Ozempic, Wegovy, Mounjaro, or Zepbound. Any form of significant weight loss can lead to similar changes in skin and muscle tone.

'Ozempic butt' highlights the broader effects of weight loss on the body, beyond just fat reduction. Preventing it involves managing the pace of weight loss and supporting skin and muscle health. For those already experiencing the condition, medical advice and potential treatments remain available as research continues.